For the quarter ended January 2024, The Cooper Companies (COO) reported revenue of $931.6 million, up 8.5% over the same period last year. EPS came in at $0.85, compared to $0.73 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $915.17 million, representing a surprise of +1.80%. The company delivered an EPS surprise of +7.59%, with the consensus EPS estimate being $0.79.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wa ...

The Cooper Companies (COO) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.59%. A quarter ago, it was expected that this surgical and contact lens products maker would post earnings of $0.87 per share when it actually produced earnings of $0.87, delivering no surprise.Over the last ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________ Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $.10 par value Nasdaq Global Select Market Emerging growth company ☐ ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to ...

PRESS RELEASE CooperCompanies Announces First Quarter 2024 Results San Ramon, Calif., February 29, 2024 — CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2024. Commenting on the results, Al White, Cooper's President and CEO said, "We're off to an outstanding start this fiscal year. We delivered record quarterly revenues in Q1 with contact lenses growing solidly and fertility posting its thirteenth consec ...

The Cooper Companies, Inc.’s (COO) first-quarter fiscal 2024 results are scheduled to be released on Feb 29, after the closing bell.In the last reported quarter, the company’s earnings were in line with the Zacks Consensus Estimate. Its earnings beat estimates in two of the trailing four quarters and met twice, delivering an average surprise of 2.84%.Q1 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $915.2 million for the soon-to-be-reported quarter, indicating a 6.6% increase from the year ...

Wall Street expects a year-over-year increase in earnings on higher revenues when The Cooper Companies (COO) reports results for the quarter ended January 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Feb ...

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Labcorp (LH) or The Cooper Companies (COO) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with st ...

SAN RAMON, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced that its four-for-one stock split will become effective on Friday, February 16, 2024, at 5:00 PM ET, and trading is expected to begin on a stock split-adjusted basis at market open on Tuesday, February 20, 2024, under the existing trading symbol "COO". The stock split supports Cooper's desire to make ownership of its stock more accessible to employees and investors. Cooper previously announced on its fourth qua ...

The Cooper Companies’ (COO) wholly-owned subsidiary CooperSurgical and Fulgent Genetics recently announced their partnership to provide exclusive newborn genetic screening panels to Cord Blood Registry (CBR) families.As a result of this collaboration, CBR by CooperSurgical brand will offer families a variety of genetic testing choices by utilizing Fulgent's Picture Genetics platform.Price PerformanceFor the past six months, COO’s shares have lost 0.3% compared with the industry’s decline of 2.3%. The S&P 50 ...

The Cooper Companies, Inc. (COO) is well-poised for growth, backed by strong prospects in its CooperVision (CVI) and CooperSurgical (CSI) business segments. Acquisitions boost the company’s portfolio and buoy optimism. However, unfavorable currency movements and rising costs continue to hurt revenues and margins, respectively.Shares of this currently Zacks Rank #3 (Hold) company have risen 11.3% in the past year compared with the industry's 10.8% growth. The S&P 500 Index has gained 22.1% in the same time f ...